Kenvue, Inc. (KVUE) Stock Research

Thursday

Kenvue reports Q2 adjusted EPS 31c, consensus 32c

KVUE

Aug 6, 6:46 AM

Over a week ago

Kenvue raises quarterly dividend 1.2% to 21c per share

KVUE

Jul 29, 6:49 AM

Kenvue confirms FDA approves Tylenol with Naproxen OTC combination

KVUE

Jul 24, 2:06 PM

FDA approves nonprescription Tylenol with Naproxen

KVUE

Jul 24, 10:14 AM

Kenvue price target raised by $1 at Barclays, here's why

KVUE

Jul 21, 6:03 AM

Kenvue price target raised by $2 at UBS

KVUE

Jul 16, 8:10 AM

What You Missed On Wall Street On Monday

+27

Jul 13, 4:25 PM

Appeals court revives autism suits against Kenvue's Tylenol, Bloomberg says

KVUE

Jul 13, 11:28 AM

Appeals court rules Kenvue must face Tylenol autism claims, Bloomberg says

KVUE

Jul 13, 11:23 AM

Kimberly-Clark price target raised by $10 at Wells Fargo, here's why

Jul 8, 6:37 AM

Kimberly-Clark price target raised by $6 at Piper Sandler, here's why

Jun 17, 6:40 AM

Mondelez names Amit Banati as CFO

Jun 15, 4:46 PM

Starboard takes new stakes in Lamb Weston and CarMax, exits Autodesk position

+13

May 15, 4:47 PM

Kenvue reports Q1 adjusted EPS 32c, consensus 26c

KVUE

May 7, 6:31 AM

Notable companies reporting before tomorrow's open

+13

May 6, 2:55 PM

Kimberly-Clark announces organizational structure after acquisition of Kenvue

Apr 15, 9:01 AM

Kenvue price target lowered by $1 at Citi, here's why

KVUE

Apr 15, 6:31 AM

Kenvue price target lowered by $1 at Barclays, here's why

KVUE

Apr 14, 8:53 AM

Kenvue Inc call volume above normal and directionally bullish

KVUE

Apr 7, 2:45 PM

Kenvue price target lowered by $1 at UBS, here's why

KVUE

Apr 7, 6:42 AM

Kenvue price target raised by $1 at Barclays, here's why

KVUE

Mar 6, 5:46 AM

What You Missed On Wall Street On Thursday

+23

Feb 26, 4:26 PM

Judge spurns Kenvue bid to dismiss Texas lawsuit over Tylenol, Reuters reports

KVUE

Feb 26, 12:19 PM

Kenvue Inc call volume above normal and directionally bullish

KVUE

Feb 20, 3:45 PM

Iconic Brand Portfolio and Market Leadership: Kenvue owns a powerful collection of highly recognized and trusted consumer health brands, including Tylenol, Neutrogena, Listerine, and Band-Aid, many of which hold leading positions in their respective categories globally.

Extensive Global Distribution Network: The company benefits from a vast and established global distribution network, ensuring its products are accessible to consumers across numerous markets worldwide, supporting diverse revenue streams.

Deep-Rooted Consumer Trust and Loyalty: Leveraging decades of heritage and association with Johnson & Johnson, Kenvue inherits a strong foundation of consumer trust, brand equity, and loyalty across its broad portfolio of health and wellness products.

Product Liability and Safety Concerns: The company faces inherent risks of product liability claims and product recalls if its consumer health products are found to be defective or cause harm, potentially leading to significant legal costs, settlements, and reputational damage.

Intense Competition and Market Share Erosion: Kenvue operates in highly competitive consumer health markets, facing pressure from established global players and emerging direct-to-consumer brands, which could lead to pricing pressure, reduced market share, and lower profitability if it fails to innovate or differentiate effectively.

Supply Chain Disruptions and Cost Volatility: Disruptions in the global supply chain, including raw material shortages, increased transportation costs, labor issues, or geopolitical events, could impact Kenvue's ability to manufacture and distribute its products, leading to higher operating costs and potential stock-outs.